In Period of Uneasy Money, Use Proteomics For Products or in the Clinic, VCs Say | GenomeWeb

If you had decided to start a proteomics company two or three years ago, you may have been one of the lucky ones. Raising venture capital to start a biotech company has never been easy, but the heightened expectations and hoopla surrounding the (stated) completion of the human genome allowed many entrepreneurs with stories of quick and easy drugs to collect hundreds of millions of dollars from venture capitalists eager to capitalize on the promise of genomics and proteomics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.